Wegovy vs. Bariatric Surgery Cost: 5-Year Financial Comparison

$1,349. That’s Wegovy’s monthly list price without insurance — or $16,188 per year for a medication you’d need indefinitely. After 5 years, you’ve spent more than the cost of gastric bypass surgery.

Wegovy (semaglutide 2.4mg, Novo Nordisk) is legitimately the most effective FDA-approved obesity medication ever cleared. Clinical trials in NEJM documented 14.9% mean total body weight loss at 68 weeks — remarkable for a medication. It’s not as good as bariatric surgery for weight loss, but it requires no surgery. The question is whether that tradeoff makes financial sense for your situation.

Wegovy Costs in 2025–2026

Wegovy’s U.S. list price is approximately $1,300–$1,600/month without insurance. The exact amount depends on your dose (0.25mg starter through 2.4mg maintenance) and pharmacy.

Note: Medicare coverage of Wegovy for obesity (not just CV risk reduction) expanded in 2024 following the SELECT trial results showing cardiovascular benefit. Eligibility requirements apply.

The 5-Year Cost Comparison: Wegovy vs. Surgery

The pattern here is clear: without insurance coverage, Wegovy is dramatically more expensive than surgery over any multi-year horizon. With strong insurance coverage on both sides, the costs are actually comparable — but surgery still delivers substantially more weight loss.

The Novo Nordisk Savings Program

Novo Nordisk operates a patient assistance program that can reduce Wegovy’s cost substantially for eligible patients:

WeGo Together savings card: Commercially insured patients may pay as little as $0/month for the first year and $25/month thereafter (eligibility restrictions apply, including income and insurance type).

NovoCare Patient Assistance: For uninsured patients below income thresholds (generally 400% of federal poverty level), Novo Nordisk may provide Wegovy free. Application required.

These programs have waitlists and eligibility requirements that change frequently. Check Novo Nordisk’s current program terms directly — don’t rely on information older than 6 months.

Weight Loss Comparison: Wegovy vs. Bariatric Surgery

The STEP trials showed mean total body weight loss with semaglutide 2.4mg of 14.9% at 68 weeks — impressive for a medication. But compare that to:

• Gastric sleeve: 25–35% total body weight loss at 2 years
• Gastric bypass: 30–40% at 2 years
• Duodenal switch: 35–45% at 2 years

For a 250-pound patient, that’s the difference between losing 37 pounds (Wegovy) and losing 62–87 pounds (surgery). For patients with severe obesity where losing 40+ pounds isn’t enough to resolve comorbidities, the clinical gap matters.

When Wegovy Is the Right Choice Despite Higher Cost

Surgery isn’t always better. Wegovy makes more financial sense when:

You have excellent insurance coverage. If your copay is $25/month and surgery costs you $25,000 out of pocket, Wegovy’s economics work for years.

Your BMI is 27–35. You don’t qualify for surgery. Wegovy is FDA-cleared at BMI ≥ 27 with a weight-related condition.

You have established cardiovascular disease. The SELECT trial (NEJM, 2023) showed semaglutide reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity and established CVD. This specific cardiovascular benefit has clinical value beyond weight loss.

You’re afraid of surgery and won’t get it. An effective medication you’ll take beats a surgery you’ll never schedule.

The Bottom Line

Without insurance, Wegovy costs $78,000–$96,000 over 5 years versus $13,500–$28,000 for gastric sleeve surgery (including ongoing costs). Surgery wins on cost for most self-pay patients, decisively. With insurance coverage that includes a low Wegovy copay, the comparison tightens, and surgery’s superior weight loss becomes the primary differentiator. Wegovy is appropriate for patients outside the surgical BMI range, with high CV risk requiring the SELECT trial benefit, or who have excellent coverage and can’t or won’t have surgery. For everyone else who qualifies for surgery — the economics favor the one-time permanent option.